Stockscreener 앱 받기
0.34
4.25%
-0.0151
시간 외 거래:
.36
0.02
+5.88%
전일 마감가:
$0.3551
열려 있는:
$0.36
하루 거래량:
386.02K
Relative Volume:
1.23
시가총액:
$21.13M
수익:
-
순이익/손실:
$-68.80M
주가수익비율:
-0.2906
EPS:
-1.17
순현금흐름:
$-59.06M
1주 성능:
-10.76%
1개월 성능:
-20.08%
6개월 성능:
-47.61%
1년 성능:
-74.91%
1일 변동 폭
$0.3307
$0.40
1주일 범위
$0.3247
$0.42
52주 변동 폭
$0.3247
$1.64
Passage Bio Inc Stock (PASG) Company Profile
명칭
Passage Bio Inc
전화
(267) 866-0312
주소
ONE COMMERCE SQUARE, PHILADELPHIA, PA
PASG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.34 | 21.13M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-29 | 재개 | Wedbush | Outperform |
| 2024-09-03 | 개시 | Rodman & Renshaw | Buy |
| 2022-03-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-19 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-07-01 | 개시 | Raymond James | Outperform |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-03-04 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-02-04 | 개시 | Guggenheim | Buy |
| 2021-01-25 | 개시 | Wedbush | Outperform |
| 2021-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-11 | 개시 | Citigroup | Neutral |
| 2020-08-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2020-03-24 | 개시 | Cowen | Outperform |
| 2020-03-24 | 개시 | Goldman | Buy |
| 2020-03-24 | 개시 | JP Morgan | Overweight |
모두보기
Passage Bio Inc 주식(PASG)의 최신 뉴스
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com
Fierce Biotech Layoff Tracker 2025: Sail cuts staff; Carisma and Inspirna shutter - Fierce Biotech
Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.35 - Investing.com
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com
Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges - Investing.com Australia
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MyChesCo
Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program - MSN
Wedbush Comments on Passage Bio’s Q1 Earnings (NASDAQ:PASG) - Defense World
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know - Nasdaq
FY2029 Earnings Forecast for Passage Bio Issued By Wedbush - Defense World
Chardan Cuts Price Target on Passage Bio to $6 From $7, Keeps Buy Rating -March 05, 2025 at 07:36 am EST - Marketscreener.com
Passage Bio (NASDAQ:PASG) Price Target Lowered to $6.00 at Chardan Capital - Defense World
Passage Bio Advances Gene Therapy for Neurodegenerative Diseases - TipRanks
Strategic Restructuring and Promising Data Catalysts Drive Buy Rating for Passage Bio - TipRanks
Chardan cuts Passage Bio stock price target to $6, maintains buy - Investing.com India
Chardan cuts Passage Bio stock price target to $6, maintains buy By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.45 - Investing.com India
Passage Bio stock plunges to 52-week low of $0.45 By Investing.com - Investing.com South Africa
Passage Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
PASSAGE BIO, INC. Full Year Loss Decreases - Nasdaq
Passage Bio Reports 2024 Financial Results and Program Advances - TipRanks
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Passage BIO, Inc. SEC 10-K Report - TradingView
Passage Bio reports FY24 EPS ($1.07) vs ($1.86) last year - TipRanks
Passage Bio Reports Fourth Quarter and Full Year 2024 Results -March 04, 2025 at 07:07 am EST - Marketscreener.com
Passage Bio Reports Promising Interim Data for PBFT02 in FTD-GRN Patients and Provides Business Updates - Nasdaq
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent - The Bakersfield Californian
Can Passage Bio's FTD-GRN Treatment Breakthrough Translate to Market Success? - StockTitan
Passage Bio to Present at Two Major Investor Conferences - MSN
Passage Bio (PASG) to Release Quarterly Earnings on Monday - Defense World
Passage Bio to Participate in Upcoming Investor Conferences - GlobeNewswire
Passage Bio Inc (PASG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):